Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia

International Journal of Cancer

Volumn 131, Issue 9, 2012, Pages 2187-2196

  Springer, Jochen ^a,b   Tschirner, Anika ^a   Hartman, Kai ^a   Palus, Sandra ^a   Wirth, Eva K ^a   Ruis, Silvia Busquets ^c   Möller, Nadine ^a   Von Haehling, Stephan ^a   Argiles, Josep M ^c   Köhrle, Josef ^a   Adams, Volker ^d   Anker, Stefan D ^a,e   Doehner, Wolfram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

cancer cachexia; oxidative stress; skeletal muscle; survival; xanthine oxidase

Indexed keywords

ALLOPURINOL; CASPASE 3; CYTOKINE; OXIPURINOL; OXYGEN RADICAL; PLACEBO; REACTIVE OXYGEN METABOLITE; URIC ACID; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CANCER SURVIVAL; DRUG MEGADOSE; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; HEPATOMA CELL; LEAN BODY WEIGHT; LOCOMOTION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY OF LIFE; RAT; URIC ACID BLOOD LEVEL; WASTING SYNDROME; WEIGHT REDUCTION;

ALLOPURINOL; ANIMALS; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CASPASE 3; ENZYME INHIBITORS; MALE; NEOPLASMS; OXIDATIVE STRESS; OXYPURINOL; RANDOM ALLOCATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME; URIC ACID; XANTHINE OXIDASE;

EID: 84865533185     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27494     Document Type: Article

References (44)

1. Tan BH, Fearon KC,. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11: 400-7.
2. Inagaki J, Rodriguez V, Bodey GP,. Proceedings: causes of death in cancer patients. Cancer 1974; 33: 568-73.
3. Hammarsten J, Hogstedt B,. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47-55. (Pubitemid 38455847)
4. Alcaino H, Greig D, Chiong M, Verdejo H, Miranda R, Concepcion R, Vukasovic JL, Diaz-Araya G, Mellado R, Garcia L, Salas D, Gonzalez L, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646-51.
5. Shi Y, Evans JE, Rock KL,. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21. (Pubitemid 37237047)
6. Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, Suh SY,. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage 2006; 31: 493-501.
7. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-7. (Pubitemid 36506072)
8. Doehner W, Landmesser U,. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 31: 433-40.
9. Hille R, Massey V,. Studies on the oxidative half-reaction of xanthine oxidase. J Biol Chem 1981; 256: 9090-5.
10. Cersosimo E, DeFronzo RA,. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22: 423-36. (Pubitemid 44774046)
11. Russell ST, Eley H, Tisdale MJ,. Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal 2007; 19: 1797-806. (Pubitemid 46935435)
12. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL,. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412. (Pubitemid 38534545)
13. Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, Baccino FM,. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92: 2783-9.
14. Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J,. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle; 2: 105-9.
15. Parks DA, Granger DN,. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl 1986; 548: 87-99. (Pubitemid 16090301)
16. Moore-Carrasco R, Busquets S, Almendro V, Palanki M, Lopez-Soriano FJ, Argiles JM,. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol 2007; 30: 1239-45.
17. Mazza A, Casiglia E, Scarpa R, Tikhonoff V, Pizziol A, Sica E, Pessina AC,. Predictors of cancer mortality in elderly subjects. Eur J Epidemiol 1999; 15: 421-7. (Pubitemid 29320918)
18. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T,. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403-9.
19. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschlager N, Hornig B, Drexler H, Harrison DG,. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003; 107: 1383-9. (Pubitemid 36350736)
20. Terada LS, Guidot DM, Leff JA, Willingham IR, Hanley ME, Piermattei D, Repine JE,. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci U S A 1992; 89: 3362-6.
21. Sarnesto A, Linder N, Raivio KO,. Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Invest 1996; 74: 48-56. (Pubitemid 26041008)
22. Doehner W, von Haehling S, Anker SD,. Uric acid as a prognostic marker in acute heart failure-new expectations from an old molecule. Eur J Heart Fail 2007; 9: 437-9. (Pubitemid 46561492)
23. Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR,. Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) 2003; 105: 425-30. (Pubitemid 37249168)
24. Doehner W, Landmesser U,. Xanthine oxidase and uric Acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 2011; 31: 433-40.
25. Doehner W, Springer J, Landmesser U, Struthers AD, Anker SD,. Uric acid in chronic heart failure-current pathophysiological concepts. Eur J Heart Fail 2008; 10: 1269-70.
26. Springer J, Fischer A,. Substance P-induced pulmonary vascular remodelling in precision cut lung slices. Eur Respir J. 2003; 22: 596-601. (Pubitemid 37258536)
27. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB,. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 1998; 12: 871-80. (Pubitemid 28294677)
28. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE,. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004; 119: 285-98. (Pubitemid 39360909)
29. Gomez-Merino D, Drogou C, Guezennec CY, Chennaoui M,. Effects of chronic exercise on cytokine production in white adipose tissue and skeletal muscle of rats. Cytokine 2007; 40: 23-9. (Pubitemid 350088496)
30. Lira FS, Rosa JC, Yamashita AS, Koyama CH, Batista ML, Jr, Seelaender M,. Endurance training induces depot-specific changes in IL-10/TNF-alpha ratio in rat adipose tissue. Cytokine 2009; 45: 80-5.
31. Lira FS, Rosa JC, Zanchi NE, Yamashita AS, Lopes RD, Lopes AC, Batista ML, Jr., Seelaender M,. Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise. Cell Biochem Funct 2009; 27: 71-5.
32. Elenkov IJ, Chrousos GP, Wilder RL,. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann N Y Acad Sci 2000; 917: 94-105.
33. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B,. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009; 1171: 59-76.
34. Stephanou A, Latchman DS,. Opposing actions of STAT-1 and STAT-3. Growth Factors 2005; 23: 177-82. (Pubitemid 43203048)
35. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR,. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997; 278: 1630-2. (Pubitemid 27516283)
36. Tisdale MJ,. Cancer cachexia. Curr Opin Gastroenterol 2009; 13: 13.
37. Ishiko O, Yoshida H, Sumi T, Hirai K, Honda K, Hyun Y, Nakagawa E, Hattori K, Ogita S,. Expression of skeletal muscle cells apoptosis regulatory proteins in plasma-perfused VX2 carcinoma-bearing rabbits. Anticancer Res 2001; 21: 2363-8. (Pubitemid 33054397)
38. van Royen M, Carbo N, Busquets S, Alvarez B, Quinn LS, Lopez-Soriano FJ, Argiles JM,. DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun 2000; 270: 533-7. (Pubitemid 30446870)
39. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marban E, Weiss RG,. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol. 2006; 290: H837-43.
40. Beck SA, Tisdale MJ,. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res. 1989; 49: 3800-4. (Pubitemid 19197400)
41. Bauhofer A, Witte K, Celik I, Pummer S, Lemmer B, Lorenz W,. Sickness behaviour, an animal equivalent to human quality of life, is improved in septic rats by G-CSF and antibiotic prophylaxis. Langenbecks Arch Surg 2001; 386: 132-40. (Pubitemid 32366491)
42. Wei L, Fahey T, Struthers AD, MacDonald TM,. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 2009; 63: 1327-33.
43. Hare JM, Mangal B, Brown J, Fisher C, Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP,. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51: 2301-9. (Pubitemid 351783365)
44. Pea F,. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol 2005; 147: 35-46. (Pubitemid 43264983)